Increased IL-33 expression in chronic obstructive pulmonary disease

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 308, Issue 7, 2015, Pages L619-L627

  Xia, Jie ^a   Zhao, Junling ^a   Shang, Jin ^a   Li, Miao ^a   Zeng, Zhilin ^a   Zhao, Jianping ^a   Wang, Jianmiao ^a   Xu, Yongjian ^a   Xie, Jungang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chronic obstructive pulmonary disease; Human bronchial epithelial cells; Interleukin 33; Peripheral blood lymphocytes

Indexed keywords

CIGARETTE SMOKE; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 33; LIPOCORTIN 5; LIPOPOLYSACCHARIDE; PROTEIN; ST2 RECEPTOR; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RAP PROTEIN, HUMAN; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; TLR4 PROTEIN, HUMAN;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYTOPLASM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PATHOGENESIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CASE CONTROL STUDY; CELL CULTURE; GENETIC ASSOCIATION; GENETICS; IMMUNOLOGY; LUNG; LYMPHOCYTE; METABOLISM; MIDDLE AGED; UPREGULATION;

AGED; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKINS; LIPOPOLYSACCHARIDES; LUNG; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTOR 4; UP-REGULATION;

EID: 84926380049     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00305.2014     Document Type: Article

References (60)

1. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 4: 499-511, 2004.
2. Aoki S, Hayakawa M, Ozaki H, Takezako N, Obata H, Ibaraki N, Tsuru T, Tominaga S, Yanagisawa K. ST2 gene expression is proliferation- dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem 335: 75-81, 2010.
3. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25: 187-191, 2000.
4. Baekkevold ES, Roussigne M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F, Brandtzaeg P, Erard M, Haraldsen G, Girard JP. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 163: 69-79, 2003.
5. Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 23: 685-691, 2004.
6. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8: 183-192, 2008.
7. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 56: 515-548, 2004.
8. Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 123: 1240-1247, 2003.
9. Beltran CJ, Nunez LE, Diaz-Jimenez D, Farfan N, Candia E, Heine C, Lopez F, Gonzalez MJ, Quera R, Hermoso MA. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 16: 1097-1107, 2010.
10. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 13: 1176-1188, 1994.
11. Bhardwaj A, Januzzi JL Jr. ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn 10: 459-464, 2010.
12. Bottcher MF, Hmani-Aifa M, Lindstrom A, Jenmalm MC, Mai XM, Nilsson L, Zdolsek HA, Bjorksten B, Soderkvist P, Vaarala O. A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharideinduced interleukin-12(p70) responses in Swedish children. J Allergy Clin Immunol 114: 561-567, 2004.
13. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378: 1015-1026, 2011.
14. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179: 2551-2555, 2007.
15. Dentener MA, Louis R, Cloots RH, Henket M, Wouters EF. Differences in local versus systemic TNFalpha production in COPD: inhibitory effect of hyaluronan on LPS induced blood cell TNFalpha release. Thorax 61: 478-484, 2006.
16. Eagan TM, Ueland T, Wagner PD, Hardie JA, Mollnes TE, Damas JK, Aukrust P, Bakke PS. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J 35: 540-548, 2010.
17. Hacker S, Lambers C, Pollreisz A, Hoetzenecker K, Lichtenauer M, Mangold A, Niederpold T, Hacker A, Lang G, Dworschak M, Vukovich T, Gerner C, Klepetko W, Ankersmit HJ. Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD. J Clin Lab Anal 23: 372-379, 2009.
18. Hamzaoui K, Kaabachi W, Fazaa B, Zakraoui L, Mili-Boussen I, Haj-Sassi F. Serum IL-33 levels and skin mRNA expression in Behcet’s disease. Clin Exp Rheumatol 31: 6-14, 2013.
19. Hang J, Zhou W, Zhang H, Sun B, Dai H, Su L, Christiani DC. TLR4 Asp299Gly and Thr399Ile polymorphisms are very rare in the Chinese population. J Endotoxin Res 10: 238-240, 2004.
20. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 109: 288-295, 2000.
21. Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, Nakanishi K, Yamanishi K. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA 110: 13921-13926, 2013.
22. Ito M, Hanaoka M, Droma Y, Kobayashi N, Yasuo M, Kitaguchi Y, Horiuchi T, Ikegawa K, Katsuyama Y, Kubo K, Ota M. The association of Toll-like receptor 4 gene polymorphisms with the development of emphysema in Japanese subjects: a case control study. BMC Res Notes 5: 36, 2012.
23. Jarvis MJ, Fidler J, Mindell J, Feyerabend C, West R. Assessing smoking status in children, adolescents and adults: cotinine cut-points revisited. Addiction 103: 1553-1561, 2008.
24. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347: 185-192, 2002.
25. Kim YS, Hwang YJ, Kim SY, Yang SM, Lee KY, Park IB. Rarity of TLR4 Asp299Gly and Thr399Ile polymorphisms in the Korean population. Yonsei Med J 49: 58-62, 2008.
26. Kunisch E, Chakilam S, Gandesiri M, Kinne RW. IL-33 regulates TNF-alpha dependent effects in synovial fibroblasts. Int J Mol Med 29: 530-540, 2012.
27. Kurokawa M, Matsukura S, Kawaguchi M, Ieki K, Suzuki S, Odaka M, Watanabe S, Homma T, Sato M, Yamaguchi M, Takeuchi H, Adachi M. Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts. Int Arch Allergy Immunol 155: 12-20, 2011.
28. Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, Komai-Koma M, Pitman N, Li Y, Niedbala W, McKenzie AN, Teixeira MM, Liew FY, Xu D. IL-33 induces antigen-specific IL-5 T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 181: 4780-4790, 2008.
29. Latiano A, Palmieri O, Pastorelli L, Vecchi M, Pizarro TT, Bossa F, Merla G, Augello B, Latiano T, Corritore G, Settesoldi A, Valvano MR, D’Inca R, Stronati L, Annese V, Andriulli A. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PloS One 8: e62144, 2013.
30. Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun 386: 181-185, 2009.
31. Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, Brumatti G, Taylor RC, Kersse K, Vandenabeele P, Lavelle EC, Martin SJ. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31: 84-98, 2009.
32. Manzano-Fernandez S, Januzzi JL, Pastor-Perez FJ, Bonaque-Gonzalez JC, Boronat-Garcia M, Pascual-Figal DA, Montalban-Larrea S, Navarro-Penalver M, Andreu-Cayuelas JM, Valdes M. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology 122: 158-166, 2012.
33. Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani K, Nagashima T, Hayakawa M, Iwamoto M, Yoshio T, Tominaga S, Minota S. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 37: 18-25, 2010.
34. Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan EYT, Lam KF, Xu DM. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology 49: 520-527, 2010.
35. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PloS One 3: e3331, 2008.
36. Murray CJ, Lopez AD. Evidence-based health policy—lessons from the Global Burden of Disease Study. Science 274: 740-743, 1996.
37. Noguchi E, Nishimura F, Fukai H, Kim J, Ichikawa K, Shibasaki M, Arinami T. An association study of asthma and total serum immunoglobin E levels for Toll-like receptor polymorphisms in a Japanese population. Clin Exp Allergy 34: 177-183, 2004.
38. Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, Fiocchi C, Vecchi M, Pizarro TT. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 107: 8017-8022, 2010.
39. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 113: 1526-1534, 2009.
40. Prefontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, Lemiere C, Martin JG, Hamid Q. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 183: 5094-5103, 2009.
41. Prefontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, Martin JG, Hamid Q. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 125: 752-754, 2010.
42. Qiu CA, Li Y, Li MC, Li M, Liu XJ, McSharry C, Xu DM. Antiinterleukin- 33 inhibits cigarette smoke-induced lung inflammation in mice. Immunology 138: 76-82, 2013.
43. Radstake TR, Franke B, Hanssen S, Netea MG, Welsing P, Barrera P, Joosten LA, van Riel PL, van den Berg WB. The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. Arthritis Rheum 50: 999-1001, 2004.
44. Rohde G, Klein W, Arinir U, Hagedorn M, Duerig N, T Bauer T, Gillissen A, Schultze-Werninghaus G, T Epplen J. Association of the ASP299GLY TLR4 polymorphism with COPD. Respir Med 100: 892-896, 2006.
45. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490, 2005.
46. Seltmann J, Werfel T, Wittmann M. Evidence for a regulatory loop between IFN-gamma and IL-33 in skin inflammation. Exp Dermatol 22: 102-107, 2013.
47. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 20: 1019-1030, 2008.
48. Smithgall MD, Comeau MR, Yoon BRP, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both T(h)1-and T(h)2-type responses through its activity on human basophils, allergen-reactive T(h)2 cells, iNKT and NK cells. Int Immunol 20: 1019-1030, 2008.
49. Su Z, Lin J, Lu F, Zhang X, Zhang L, Gandhi NB, de Paiva CS, Pflugfelder SC, Li DQ. Potential autocrine regulation of interleukin-33/ ST2 signaling of dendritic cells in allergic inflammation. Mucosal Immunol 6: 921-930, 2013.
50. Sundlisaeter E, Edelmann RJ, Hol J, Sponheim J, Kuchler AM, Weiss M, Udalova IA, Midwood KS, Kasprzycka M, Haraldsen G. The alarmin IL-33 is a notch target in quiescent endothelial cells. Am J Pathol 181: 1099-1111, 2012.
51. Suzukawa M, Likura M, Koketsu R, Nagase H, Tamura C, Komiya A, Nakae S, Matsushima K, Ohta K, Yamamoto K, Yamaguchi M. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol 181: 5981-5989, 2008.
52. Tang Y, Guan Y, Liu Y, Sun J, Xu L, Jiang Y. The role of the serum IL-33/sST2 axis and inflammatory cytokines in chronic obstructive pulmonary disease. J Interferon Cytokine Res 34: 162-168, 2014.
53. Tominaga S. A putative protein of a growth specific cDNA from BALB/ c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 258: 301-304, 1989.
54. Verri WA Jr, Guerrero AT, Fukada SY, Valerio DA, Cunha TM, Xu D, Ferreira SH, Liew FY, Cunha FQ. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci USA 105: 2723-2728, 2008.
55. Verri WA Jr, Souto FO, Vieira SM, Almeida SC, Fukada SY, Xu D, Alves-Filho JC, Cunha TM, Guerrero AT, Mattos-Guimaraes RB, Oliveira FR, Teixeira MM, Silva JS, McInnes IB, Ferreira SH, Louzada-Junior P, Liew FY, Cunha FQ. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis 69: 1697-1703, 2010.
56. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187: 347-365, 2013.
57. Xu D, Chan WL, Leung BP, Huang FP, Wheeler R, Piedrafita D, Robinson JH, Liew FY. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 187: 787-794, 1998.
58. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 30: 825-830, 2011.
59. Yang QT, Li G, Zhu YB, Liu L, Chen E, Turnquist H, Zhang XG, Finn OJ, Chen XC, Lu BF. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8() T cells. Eur J Immunol 41: 3351-3360, 2011.
60. Zhiguang X, Wei C, Steven R, Wei D, Wei Z, Rong M, Zhanguo L, Lianfeng Z. Over-expression of IL-33 leads to spontaneous pulmonary inflammation in mIL-33 transgenic mice. Immunol Lett 131: 159-165, 2010.